{"nctId":"NCT01737398","briefTitle":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","startDateStruct":{"date":"2013-03-15","type":"ACTUAL"},"conditions":["FAP","Familial Amyloid Polyneuropathy","TTR","Transthyretin","Amyloidosis"],"count":173,"armGroups":[{"label":"Inotersen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Inotersen"]},{"label":"Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Inotersen","otherNames":["TEGSEDI","IONIS-TTR Rx","ISIS 420915"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage 1 and Stage 2 FAP participants with the following:\n\n  1. NIS score within protocol criteria\n  2. Documented transthyretin variant by genotyping\n  3. Documented amyloid deposit by biopsy\n* Females of child-bearing potential must use appropriate contraception and be non-pregnant and non-lactating. Males engaging in relations of child-bearing potential are to use appropriate contraception\n\nExclusion Criteria:\n\n* Low Retinol level at screen\n* Karnofsky performance status ≤50\n* Poor Renal function\n* Known type 1 or type 2 diabetes mellitus\n* Other causes of sensorimotor or autonomic neuropathy (for example, autoimmune disease)\n* If previously treated with Vyndaqel®, will need to have discontinued treatment for 2 weeks prior to Study Day 1. If previously treated with Diflunisal, will need to have discontinued treatment for 3 days prior to Study Day 1\n* Previous treatment with any oligonucleotide or siRNA within 12 months of screening\n* Prior liver transplant or anticipated liver transplant within 1 year of screening\n* New York Heart Association (NYHA) functional classification of ≥3\n* Acute Coronary Syndrome or major surgery within 3 months of screening\n* Known Primary or Leptomeningeal Amyloidosis\n* Anticipated survival less than 2 years\n* Any other conditions in the opinion of the investigator which interfere with the participant participating in or completing the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"82 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score at Week 66","description":"The mNIS+7 composite score is a measure of neurologic impairment that evaluates muscle weakness, sensation, reflexes, nerve conduction, and autonomic function. The mNIS+7 Composite Score has a range of -22.32 to 346.32 and a higher mNIS+7 composite score indicates lower function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.16","spread":"15.672"},{"groupId":"OG001","value":"23.89","spread":"24.190"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline In The Norfolk Quality Of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66","description":"The Norfolk QoL-DN score is a measure of physical function/large fiber neuropathy, symptoms, activities of daily living, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN total score has a range of -4 to 136, and a higher Norfolk QoL-DN score indicates poorer QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"18.967"},{"groupId":"OG001","value":"10.77","spread":"21.134"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline In The Norfolk QoL-DN Questionnaire Symptoms Domain Score at Week 66","description":"The Norfolk QoL-DN symptoms score is a sub-score of the total Norfolk QoL-DN Questionnaire. The Norfolk QoL-DN symptoms domain score has a range of 0-32, and a higher Norfolk QoL-DN score indicates poorer QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.40","spread":"4.763"},{"groupId":"OG001","value":"1.18","spread":"5.270"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline In The Norfolk QoL-DN Questionnaire Physical Functioning/Large Fiber Neuropathy Domain Score at Week 66","description":"The Norfolk QoL-DN physical functioning/large fiber neuropathy domain score is a sub-score of the total Norfolk QoL-DN Questionnaire. The Norfolk QoL-DN physical function/large fiber neuropathy domain score has a range of -4 to 56, and a higher Norfolk QoL-DN domain score indicates poorer QoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"11.924"},{"groupId":"OG001","value":"8.74","spread":"9.689"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline In Modified Body Mass Index (mBMI) at Week 65","description":"The mBMI is the BMI multiplied by the serum albumin g/L","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.32","spread":"96.311"},{"groupId":"OG001","value":"-85.21","spread":"91.259"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline In Body Mass Index (BMI) at Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"1.521"},{"groupId":"OG001","value":"-0.87","spread":"1.202"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neuropathy Impairment Score (NIS) at Week 66","description":"The NIS score is a measure of neurologic impairment. The NIS Score has a range of 0 to 244 and a higher NIS score indicates lower function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.47","spread":"10.329"},{"groupId":"OG001","value":"17.29","spread":"16.986"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified +7 at Week 66","description":"The Modified +7 score is a version of the NIS score that is a measure of neurologic impairment. The Modified +7 Score has a range of -22.32 to 102.32 and a higher NIS score indicates lower function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"11.134"},{"groupId":"OG001","value":"6.60","spread":"12.770"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in NIS+7 at Week 66","description":"The NIS+7 score is a version of the NIS score that is a measure of neurologic impairment. The NIS+7 Score has a range of -26.04 to 270.04 and a higher NIS score indicates lower function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.10","spread":"10.709"},{"groupId":"OG001","value":"19.00","spread":"16.824"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram (ECHO) at Week 65 in the CM-ECHO Set","description":"GLS by ECHO is a measure of cardiac systolic function","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"3.134"},{"groupId":"OG001","value":"0.46","spread":"2.702"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Global Longitudinal Strain (GLS) by Echocardiogram ECHO at Week 65 in the ECHO Subgroup","description":"GLS by ECHO is a measure of cardiac systolic function","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"3.163"},{"groupId":"OG001","value":"1.05","spread":"2.745"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Transthyretin (TTR) Level at Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1570","spread":"0.0619"},{"groupId":"OG001","value":"-0.0146","spread":"0.0402"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Retinol Binding Protein 4 (RBP4) Level at Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21725.9","spread":"9884.04"},{"groupId":"OG001","value":"-1768.7","spread":"8027.78"}]}]}]},{"type":"SECONDARY","title":"Maximum Measured Plasma Concentration (Cmax) Of Inotersen At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.76","spread":"1.88"},{"groupId":"OG001","value":"11.1","spread":"4.80"}]}]}]},{"type":"SECONDARY","title":"Time To The Maximum Plasma Concentration (Tmax) Of Inotersen At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":"1.88"},{"groupId":"OG001","value":"3.48","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Area Under The Plasma Concentration-time Curve From 0 To 24 Hours (AUC[0-24hr]) Of Inotersen At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":"30.7"},{"groupId":"OG001","value":"92.4","spread":"77.3"}]}]}]},{"type":"SECONDARY","title":"Area Under The Plasma Concentration-time Curve From 0 To 168 Hours (AUC[0-168hr]) Of Inotersen At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":"33.5"},{"groupId":"OG001","value":"103.0","spread":"88.2"}]}]}]},{"type":"SECONDARY","title":"Plasma Clearance From 0 To 24 Hours (CL[0-24hr]/F) Of Inotersen At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"1.32"},{"groupId":"OG001","value":"6.14","spread":"5.92"}]}]}]},{"type":"SECONDARY","title":"Inotersen Plasma Clearance At Steady State (CLss/F) At Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":"1.21"},{"groupId":"OG001","value":"5.46","spread":"5.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":112},"commonTop":["Nausea","Fatigue","Diarrhoea","Injection site erythema","Headache"]}}}